Tag: Commercialization

 

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions.    

Logo
Logo

Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.

Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.

The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.

In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function

111 to be the Omni-channel Drug Commercialization Partner of Xiangxu Pharmaceutical for Traditional Chinese Medicine

SHANGHAI, Oct. 15, 2020 /PRNewswire/ — On September 24, 111, Inc. (the “Company” or “111″) and Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue Pharmaceutical”) officially signed a strategic partnership agreement (the “Agreement”) to deepen collaboration to further develop the “Internet + Medicine” model for China’s traditional Chinese medicine industry.

Per the Agreement, 111 will become an omni-channel commercialization partner of Xiangxue Pharmaceutical. Through the integration of Smart Supply Chain, digital marketing, data capabilities, and cloud services, Xiangxue Pharmaceutical will be able to promote its abundant traditional Chinese medicine products into new markets through online and offline platforms, as well as expanding into existing markets.

As the pioneer in “Internet + Medicine” platform, 111 has built China’s largest digital healthcare platform that combines both online and offline channels covering 280,000 pharmacies nationwide. In the often underserved tier 3-6 cities, 111 covers over 63% of retail pharmacies. The Agreement aims to combine the strength of 111′s omni-channel drug commercialization platform and Xiangxue Pharmaceutical’s expansive portfolio of products to drive the growth of traditional Chinese medicine. Both companies are excited to embark on this symbiotic partnership that aims further strengthen 111′s capabilities of connecting pharmaceutical companies with patients in need of their medicine.

Mr. ZHU Pengcheng, Co-COO of 111, commented that he has full confidence in this mutually beneficial partnership that leverages the expertise of both companies to service and promote the traditional Chinese medicine industry by combining 111′s leading digital healthcare platform and Xiangxue Pharmaceutical’s innovative product line. The two parties will collaborate in big data application, digital marketing of traditional Chinese medicine, brand building, and patient health management to optimize operations and better serve patients’ needs.

Mr. TAN Guanghua, General Manager of the Marketing Center of Xiangxue Pharmaceutical, commented that 111, as China’s leading digital healthcare platform, has tremendous competitive advantages in its technology-enabled Smart Supply Chain, omni-channel drug commercialization capabilities, and smart technology and integrated online-offline infrastructure that leverages the latest in AI, cloud-based solutions, and big data. The Agreement combines the expertise of both companies and he has full confidence that the strategic partnership will be a success in achieving significant annual sales growth for Xiangxue Pharmaceutical.

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical is specialized in the health industry, covering fields such as traditional Chinese medicine decoction pieces, Chinese patent medicine, functional healthcare products, biomedical engineering, and life science research. It has built large GAP medicinal materials planting bases and GMP production bases, building an integrated industrial chain that includes traditional Chinese medicine resources development, new drug R&D and production, advanced manufacturing of traditional Chinese medicine, and modern logistics and distribution. The company has become a leading traditional Chinese medicine modernization company with proprietary intellectual property rights, its brands and self-dependent innovation ability.

About 111, Inc.

111, Inc. (NASDAQ: YI) (“111” or the “Company”) is a leading digital healthcare platform committed to digitally connecting patients with healthcare products and services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy,